Given that our data identifies SOX4 and SMARCA4 as key modulators of TGFBR2 expression and PI3K activity in basal-like breast cancer, it remains to be determined if aberrant TGFBR2 activity can also regulate a similar resistance mechanism to PI3K-family inhibitors in TNBC patients. The gene discussed is SMARCA4; the disease is breast cancer.